eyal

Quark reached agreement with FDA on the overall Phase 3 trial design with a new innovative primary endpoint
Fremont, CA –  July 9, 2018 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced the first patient dosed in the […]

FREMONT, Calif., Oct. 9, 2017 Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, is delivering an oral presentation at the 6th Annual RNAi China Conference in Jiangsu.

The presentation will summarize the preclinical efficacy data for inhaled small interfering RNA (siRNA) against an undisclosed […]

QPI 1002 Meets Primary & Multiple Secondary Endpoints
A statistically significant reduction in AKI incidence following cardiac surgery was demonstrated
First multicenter Phase 2 clinical study with an investigational drug for the prevention of AKI to meet primary endpoint
QPI-1002 appears to be well tolerated with no safety issues identified

Fremont, CA – July 27, 2017 – Today, Quark […]

FREMONT, Calif., October 14, 2016 — Quark Pharmaceuticals, Inc. today announced the launch of www.EyeActNow.com to promote public awareness and subject recruitment for a global Phase II/III clinical study evaluating QPI-1007, an investigational drug designed to stop further vision loss in patients with early diagnosis of Non-arteritic Anterior Ischemic Optic Neuropathy, or NAION.

Often referred to […]

FREMONT, Calif., Sept. 19, 2016 — Today, at the RNA Therapeutics Summit in Berlin, Germany, Quark Pharmaceuticals Inc. Chief Scientific Officer Dr. Elena Feinstein will provide an overview of Quark’s clinical and non-clinical pipelines of siRNA therapeutics focused on non-liver indications to address additional urgent unmet medical needs. RNA Therapeutics Summit is an international gathering […]

Treatment for Non-Arteritic Ischemic Optic Neuropathy is
in Phase II/III Study

FREMONT, Calif., July 28, 2016 — Quark Pharmaceuticals, Inc. (“Quark”) today announced that the United States Patent and Trademark Office (“USPTO”) has granted a key patent covering the treatment of patients suffering from non-arteritic anterior ischemic optic neuropathy (“NAION”) with the Company’s ocular neuroprotectant QPI-1007. The […]